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Abstract
Background: It has not previously been reported that sildenafil citrate causes malignant
arrhythmias in humans.
Case presentation: A 41-year-old man developed sustained ventricular tachycardia following
sildenafil citrate administration.
Conclusion: It cannot be dismissed that this patient experienced ventricular tachycardia as an
adverse effect of sildenafil citrate administration.
Background
Concerns about the safety of sildenafil citrate (Viagra®)
have previously been raised [1]. Other case reports and
studies have described electrophysiological changes asso-
ciated with ventricular arrhythmias following administra-
tion of sildenafil citrate [2-4].
We describe a case of a young man with no cardiac history
or family history of heart disease or sudden death, devel-
oping sustained ventricular tachycardia after ingestion of
sildenafil citrate. This case highlights a potential adverse
effect of sildenafil citrate and the possible morbidity and
potential lethality associated with this adverse effect.
Case presentation
In August, 2006, a 41-year-old man was transferred after
an episode of sustained monomorphic ventricular tachy-
cardia (VT). There was no history of any cardiopulmonary
symptoms and no family history of heart disease or sud-
den death. The arrhythmia started after 90 minutes of
moderate pace swimming. In the locker room the patient
felt dizzy, had a feeling of tachycardia and experienced a
brief, witnessed syncope. At admission to the referring
hospital VT with a frequency of 220 min-1 was docu-
mented (figure 1). Blood pressure was 105/60 mmHg.
Before transferral, the VT was treated with metoprolol 2
milligrams and amiodarone 300 milligrams intrave-
nously and converted to sinus rhythm.
Approximately 10 hours prior to the arrhythmia the
patient had taken sildenafil citrate (Viagra®) 100 mg
orally, which had been prescribed because of erectile dys-
function. He was not taking any other medication. Blood
tests were unremarkable except for troponin T (0.82
mikrograms/Liter) and CKMB (40.8 mikrograms/Liter).
Resting ECG, bicycle ergometer exercise testing, echocar-
diography with tissue Doppler imaging, coronary angiog-
raphy and cardiac nuclear magnetic resonance scanning
were all normal. Six endomyocardial biopsies from the
right ventricle showed slight non-specific hypertrophy
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mogenic right ventricle cardiomyopathy. An electrophysi-
ological study using protocol stimulation in the apex and
the outflow tract of the right ventricle induced 10 beats of
non-sustained VT with alternating morphology. On a sub-
sequent day, an additional electrophysiological study was
conducted 41/2 hours following administration of 100
mg of Viagra® orally (serum concentration 0.36 mg/kg).
On that occasion a non-sustained VT over 24 beats identi-
cal to the VT at admission was induced (figure 2). A pro-
phylactic implantable cardioverter defibrillator (ICD) was
implanted and the patient was instructed not to use silde-
nafil. At a follow-up visit in December 2006 interrogation
of the ICD revealed that two events of VT had been
detected and terminated by anti tachycardia pacing.
Discussion and conclusion
Sildenafil citrate is widely used to treat male erectile dys-
function and therapeutic uses for other diseases such as
pulmonary hypertension are emerging. Sildenafil citrate
has proven to be safe when used in the treatment of erec-
tile dysfunction of organic, psychogenic or mixed causes
[5]. Concerns about the effects of phosphodiesterase-5
inhibitors on the heart and their safety in patients with
cardiovascular disease have been raised. The concerns
include effects on blood pressure, heart rate and cardiac
electrophysiology. This led to the publishing of a report
from the U.S. Food and Drug Administration, describing
deaths in patients having been prescribed sildenafil citrate
in the first period after the marketing from late March
through mid-November 1998 [1]. In this period, >6 mil-
lion outpatient prescriptions were dispensed. Of the 130
confirmed deaths among men (mean age, 64 years) who
received sildenafil citrate, 77 had cardiovascular events,
including 41 with myocardial infarction and 27 with car-
diac arrest. Cause of death was unknown in 48 and non-
cardiac in 5 men. The time from drug ingestion to death
or onset of symptoms leading to death was <5 hours for
44 men, later the same day; 6 men, the next day; 8 men,
two to seven days later; 9 men and unknown for the
remainder. Sildenafil citrate blocks the rapid component
of the delayed rectifier potassium current in guinea pig
hearts [2] and produces small but significant increases in
the QTc interval in humans [3]. Sildenafil has been
reported to cause VT in pigs when administered in combi-
nation with a nitric oxide donor [4].
We conclude that our patient had no confirmable cardiac
condition other than VT. The hypothesis, that this patient,
with documented episodes of non-sustained VT, experi-
enced an episode of sustained VT caused by sildenafil cit-
rate lowering the VT threshold, cannot be dismissed.
Sustained ventricular tachycardia in a 41-year-old man receiving sildenafil therapyFigure 1
Sustained ventricular tachycardia in a 41-year-old man receiving sildenafil therapy. Original tracing when the patient was admit-
ted to the hospital.Page 2 of 4
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1. VT: Ventricular tachycardia
2. ICD: Implantable cardioverter defibrillator
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